MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1093/ofid/ofy331

Медицинская библиотека · Open forum infectious diseases · 2018

Dalbavancin for the Treatment of Osteomyelitis in Adult Patients: A Randomized Clinical Trial of Efficacy and Safety.

Rappo Urania, Puttagunta Sailaja, Shevchenko Vadym, Shevchenko Alena, Jandourek Alena, Gonzalez Pedro L, Suen Amy, Mas Casullo Veronica, Melnick David, Miceli Rosa, Kovacevic Milan, De Bock Gertjan, Dunne Michael W

СтатьяПеревод в очереди

Аннотация

BACKGROUND

Osteomyelitis is a challenging infection that can involve 4-6 weeks of intravenous (IV) antibiotics. Dalbavancin, approved for acute bacterial skin and skin structure infections, has potent activity against gram-positive pathogens. This study assessed the efficacy and safety of dalbavancin as a 2-dose regimen for osteomyelitis.

METHODS

This study was a randomized, open-label, comparator-controlled trial in adults with a first episode of osteomyelitis defined by clinical symptoms, radiologic findings, and elevated C-reactive protein. Patients were randomized 7:1 to dalbavancin (1500 mg IV on days 1 and 8) or standard of care (SOC) for osteomyelitis (oral or IV) per investigator judgment for 4-6 weeks. The primary endpoint was clinical response at day 42, defined as recovery without need for additional antibiotics in the clinically evaluable (CE) population. Clinical response was also assessed at day 21, 6 months, and 1 year.

RESULTS

Eighty patients were randomized to dalbavancin (n = 70) or SOC (n = 10). All had baseline debridement; Staphylococcus aureus was the most common pathogen (60% of patients). Clinical cure at day 42 was seen in 65/67 (97%) and 7/8 (88%) patients in the dalbavancin group and SOC group in the CE population, respectively. Clinical response was similar in the dalbavancin group at day 21 (94%), 6 months, and 1 year (96%). Treatment-emergent adverse events occurred in 10 patients in the dalbavancin group; no patient discontinued treatment due to an adverse event.

CONCLUSIONS

A 2-dose regimen of weekly dalbavancin is effective and well tolerated for the treatment of osteomyelitis in adults.

CLINICAL TRIALS REGISTRATION: NCT02685033.

Для цитирования: Rappo Urania, Puttagunta Sailaja, Shevchenko Vadym, Shevchenko Alena, Jandourek Alena, Gonzalez Pedro L, Suen Amy, Mas Casullo Veronica, Melnick David, Miceli Rosa, Kovacevic Milan, De Bock Gertjan, Dunne Michael W. Dalbavancin for the Treatment of Osteomyelitis in Adult Patients: A Randomized Clinical Trial of Efficacy and Safety.. Open forum infectious diseases. 2018. DOI: 10.1093/ofid/ofy331.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.